EQL Pharma: Memprex© (methenamine hippurate) license signed with partner for Hungary

There is currently no product with methenamine hippurate offered in Hungary. Memprex© offers an alternative for treatment of recurring urinary tract infections which is both noninferior to long-term antibiotics and which doesn't increase the risk to develop antibioticresistant bacteria since it is an antiseptic treatment rather than an antibiotic. Hungary is a country of approx. 9.5 million people. For reference, Sweden with 10,7 million people had pharmacy market sales of methenamine hippurate close to 20 MSEK in 2025. For the exclusive rights to Memprex® in Hungary, Pharmacenter will, subject to reaching agreed sales, pay a five-figure sum in EUR spread over three milestones. The product will be supplied by EQL to Pharmacenter using a transfer price.

About Memprex®

Memprex® is taken as a tablet containing 1g of the substance methenamine hippurate. It is indicated as a prophylactic treatment for patients, mainly women, troubled by recurring urinary tract infections. As a prophylactic treatment Memprex® is taken twice daily by the patient even when the patient isn't showing any symptoms of an infection.

About EQL

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 49 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others. Press Release Lund August 12, 2026 EQL Pharma AB (publ) Org.nr. 556713-3425

About Pharmacenter

Founded in 2002, Pharmacenter Hungary is an independent Hungarian pharmaceutical company focused on building, developing and commercializing its own and in-licensed portfolio of medicinal products with a strong focus on oncology, urology, and hospital products in Hungary. Pharmacenter has a strong track record of pioneering new pharmaceutical therapies in Hungary, having introduced the country's first orphan medicinal product and its first biosimilar medicine to the Hungarian market. With more than 20 years of experience in the Hungarian healthcare segment, Pharmacenter has built strong commercial and market access capabilities and an established presence in both the prescription and hospital pharmaceutical markets. The company is a market leader in Hungary in closed-system drug transfer solutions, supporting the safe handling of hazardous medicines, particularly in oncology settings.